Status of vaccine research and development for Shigella (Q34518265)

2 August 2017

Status of vaccine research and development for Shigella (English)

1 reference

2 August 2017

1 reference

2

Thomas Wierzba

1 reference

2 August 2017

Sachin Mani

1

1 reference

PubMed ID

26979135

2 August 2017

Richard I Walker

series ordinal

3

1 reference

PubMed ID

26979135

2 August 2017

language of work or name

English

0 references

publication date

12 March 2016

1 reference

2 August 2017

1 reference

2 August 2017

34

1 reference

2 August 2017

26

1 reference

2 August 2017

2887-2894

1 reference

Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Global causes of diarrheal disease mortality in children <5 years of age: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Estimating diarrheal illness and deaths attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents, and adults in South Asia and Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Pathogenesis, virulence, and infective dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Changing emergence of Shigella sero-groups in Bangladesh: observation from four different diarrheal disease hospitals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Shigella isolates from the global enteric multicenter study inform vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Immunity in Shigellosis. II. Protection Induced by Oral Live Vaccine or Primary Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Epidemiology of Shigella-associated diarrhea in rural Egyptian children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Recent progress towards development of a Shigella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Inactivated and subunit vaccines to prevent shigellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Live-attenuated Shigella vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Shigella manipulates host immune responses by delivering effector proteins with specific roles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Progress and pitfalls in Shigella vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Serum bactericidal assays to evaluate typhoidal and nontyphoidal Salmonella vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Establishment of a Shigella sonnei human challenge model in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

The Shigella human challenge model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Enhancing oral vaccine potency by targeting intestinal M cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Immunomodulation of gut-associated lymphoid tissue: current perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Defending the mucosa: adjuvant and carrier formulations for mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Cross-protection provided by live Shigella mutants lacking major antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Broadly protective Shigella vaccine based on type III secretion apparatus proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

High yield production process for Shigella outer membrane particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

7 January 2021

Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

7 January 2021

Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

7 January 2021

Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.075

7 January 2021

10.1016/J.VACCINE.2016.02.075

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

26979135